Technical Analysis for SVA - Sinovac Biotech Ltd

Grade Last Price % Change Price Change
grade D 6.49 -0.15% -0.0100
SVA closed down 0.15 percent on Friday, January 25, 2019, on 21 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical SVA trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -0.15%
Doji - Bullish? Reversal -0.15%
Down 3 Days in a Row Weakness -0.15%
Down 4 Days in a Row Weakness -0.15%
Older signals for SVA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase I/II clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Medicine Health RTT Biopharmaceutical Vaccines Influenza Vaccination Epidemiology Measles Rubella Varicella Mumps Seasonal Influenza

Is SVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.6352
52 Week Low 6.25
Average Volume 30,445
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 7.0150
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.0520
MACD Signal Line -0.0104
MACD Histogram -0.0416
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.7600
Resistance 3 (R3) 6.7333 6.6167 6.7150
Resistance 2 (R2) 6.6167 6.5479 6.6300 6.7000
Resistance 1 (R1) 6.5533 6.5054 6.4950 6.5800 6.6850
Pivot Point 6.4367 6.4367 6.4075 6.4500 6.4367
Support 1 (S1) 6.3733 6.3679 6.3150 6.4000 6.2950
Support 2 (S2) 6.2567 6.3254 6.2700 6.2800
Support 3 (S3) 6.1933 6.2567 6.2650
Support 4 (S4) 6.2200